In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates

被引：0
作者：
Yongbo Zhang
Peizhen Li
Yuhan Yin
Fuqiang Li
Qinghua Zhang
机构：
[1] An Qiu People’s Hospital,Department of Respiratory Medicine
[2] Liao Cheng Dong Chang Fu People’s Hospital,Department of Clinical Laboratory
[3] Yi Shui People’s Hospital,Department of Clinical Laboratory
来源：
The Journal of Antibiotics | 2017年 / 70卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：193 / 195
页数：2
相关论文
共 43 条
  • [1] Yim H(2011)Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Ann. Clin. Lab. Sci. 41 39-43
  • [2] Tzouvelekis LS(2012) and Clin. Microbiol. Rev. 25 682-707
  • [3] Markogiannakis A(2006)Carbapenemases in Expert. Rev. Anti. Infect. Ther. 4 9-25
  • [4] Psichogiou M(2011) and other Expert Opin. Drug Metab. Toxicol. 7 1459-1470
  • [5] Tassios PT(2011): an evolving crisis of global dimensions Lancet Infect. Dis. 11 834-844
  • [6] Daikos GL(2011)Tigecycline: a novel glycylcycline antibiotic Antimicrob. Agents Chemother. 55 1420-1427
  • [7] Zhanel GG(2014)Pharmacokinetic and pharmacodynamic evaluation of tigecycline Biomed. Res. Int. 2014 397421-555
  • [8] Karlowsky JA(2015)Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis J. Antibiot. (Tokyo) 68 551-796
  • [9] Rubinstein E(2013) pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Lancet. Infect. Dis. 13 785-663
  • [10] Hoban DJ(2014) isolates producing a KPC carbapenemase Antimicrob. Agents Chemother. 58 654-1353
12345